Skip to main content
Fig. 2 | BMC Rheumatology

Fig. 2

From: Serum levels of reactive oxygen metabolites at 12 weeks during tocilizumab therapy are predictive of 52 weeks-disease activity score-remission in patients with rheumatoid arthritis

Fig. 2

Changes in ROM serum levels in 52 weeks-DAS-remission group (straight green line) and non-remission group (dotted blue line). *Significant difference between 52 weeks-DAS-remission and non-remission group, p < 0.05. ROM: reactive oxygen metabolites; DAS: disease activity score

Back to article page